Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
COMBAT-CRPC trial: what clinicians have said so far
COMbination of Bipolar Androgen Therapy and Nivolumab
- NCT03554317 ↗
- Completed
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on COMBAT-CRPC (testosterone plus nivolumab in metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on COMBAT-CRPC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- COMbination of Bipolar Androgen Therapy and Nivolumab in Patients With Metastatic Castration-Resistant Prostate Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Castration-resistant Prostate Cancer; Metastatic Prostate Cancer; Prostate Cancer
- Interventions
- Testosterone cypionate; Nivolumab
- Arms
- Bipolar Androgen Therapy + Nivolumab · Experimental
- Enrollment
- 45
- Primary outcomes
- Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy + Nivolumab
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins with Bristol-Myers Squibb
- Start
- Sep 5, 2018
- Primary completion
- Oct 27, 2022
- Results posted
- Yes
- Registry record
- NCT03554317 · updated Feb 20, 2024
Publications
linked from the registry- Markowski MC, Taplin ME, Aggarwal R, Sena LA, Wang H, Qi H, Lalji A, Sinibaldi V, Carducci MA, Paller CJ, Marshall CH, Eisenberger MA, Sanin DE, Yegnasubramanian S, Gomes-Alexandre C, Ozbek B, Jones T, De Marzo AM, Denmeade SR, Antonarakis ES. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nat Commun. 2024 Jan 2;15(1):14. doi: 10.1038/s41467-023-44514-2. PubMed 38167882